In the Intuniv case, Faruqi & Faruqi represents a class of direct purchasers of Shire’s Intuniv (guanfacine), a prescription drug used to treat attention deficit hyperactivity disorder. The class also includes direct purchasers of generic versions of Intuniv from Actavis, Shire’s former co-defendant and alleged co-conspirator. Actavis has already settled for $19.9 million while litigation as to Shire remains ongoing. The complaint alleges that Shire entered a reverse payment patent settlement with Actavis to delay launching its first-filed generic to compete with Shire’s $300+ million a year Intuniv tablets. Such an agreement violates §§ 1 and 2 of the Sherman Act.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 01/11/2017
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771